METHODS: This study is a retrospective cohort study using a large, nationwide database of administrative health claims for members of large commercial and Medicare Advantage health plans. We identified adult patients newly diagnosed with NHL between January 01, 2017 and June 30, 2021. We matched NHL patients to non-cancer controls using age, sex, race and ethnicity, and year of diagnosis at a ratio of 1:5. We then estimated age-, sex-, race and ethnicity-, comorbidity-, and diagnosis year-adjusted spending (total and patient out-of-pocket [OOP], medical and pharmacy) of cases and controls within one year after index diagnosis. For non-cancer controls, we randomly assigned an index date to them. We used generalized linear model with gamma family to estimate the adjusted spending.